HTA outcome for ATMPs in the three Scandinavian countries Sweden, Norway, Denmark

What is the outcome of ATMPs that has been approved by the EMA in the Scandinavian markets?
Read now
The long road to EU HTA: An update to the current status of implementation
The European Union’s new Regulation (EU) 2021/2282 on health technology assessment creates the legal and organizational framework for cooperation between member states in joint scientific consultations (JSCs) and joint clinical assessments (JCAs) of certain new therapies for the first time. The joint assessments will impact all centrally authorized medicines and some medical devices and serve as the basis for national value assessments and price negotiations. This regulation is now in force and will bring important and wide-reaching changes that pharmaceutical companies need to understand.
The P&R landscape of Orphan Drugs in Spain
The PHAROS network member Omakase Consulting shares their last report, in collaboration with the ObserveMHe platform, about the Pricing and Reimbursement situation in Spain of Orphan Drugs approved by the European Commission until 2021 (included).